Physician

Alan R Alberts, MD

According to 2025 Medicare claims, Alan Alberts, MD (NPI: 1487643672) practices rheumatology in the Fort Lauderdale-Pompano Beach-Sunrise, FL market, with the plurality of this provider's patient population coming from Broward, FL. This provider's primary affiliated billing organization is AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES LLC (NPI: 1598205072; TIN: 831053374) and primary practice location at 33321-2956.

Alberts' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 145 traditional Medicare patients, billed 27,682 HCPCS/CPT codes, and received $237,305 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,422 prescription claims across 495 beneficiaries totaling $1,540,895 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 47 records totaling $256,332. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $193,229 and ending at $237,305. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $430,640 to $1,540,895. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	248	11,504	$193,229
2016	256	16,296	$242,849
2017	221	16,896	$286,802
2018	220	29,088	$411,405
2019	205	35,229	$413,561
2020	173	31,893	$365,363
2021	161	18,764	$209,428
2022	162	17,684	$192,208
2023	167	35,984	$286,904
2024	145	27,682	$237,305

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	435	3,289	$430,640
2016	423	3,017	$492,714
2017	434	2,807	$559,477
2018	475	2,991	$845,743
2019	444	2,867	$842,975
2020	412	2,656	$822,842
2021	435	2,479	$781,015
2022	451	2,386	$993,171
2023	477	2,615	$1,054,697
2024	495	2,422	$1,540,895

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	25	25	$163
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	41	47	$122
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	122	259	$91
77080	Dxa bone density measurement of hip, pelvis, spine	19	19	$38
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	42	83	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	36	1,064	$270,951
Cimzia (2 Pack)	Certolizumab Pegol	31	868	$179,671
Orencia	Abatacept/Maltose	28	784	$114,562
Cosentyx Sensoready Pen	Secukinumab	11	329	$111,698
Prolia	Denosumab	61	10,980	$107,566

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	42	$2,046	AstraZeneca UK Limited
Research Payments	Reported research-related payment or transfer-of-value amount.	5	$254,286	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alan R. Alberts, MD?

Tedicare shows public-source Medicare data for Alan R. Alberts, MD (NPI 1487643672), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alan R. Alberts, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alan R. Alberts, MD?

Alan R. Alberts, MD is linked to AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES LLC (billing NPI 1598205072) in the available physician profile data.

Does Alan R. Alberts, MD have Open Payments data?

Alan R. Alberts, MD has 47 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.